An interlocking drug infusion device includes a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the piston forward by rotation; a driving unit, the driving unit moved in a driving direction to drive the driving wheel to rotate; an actuator, electrically connected to the driving unit, used to provide power for the driving unit in the driving direction after energized; a program module, electrically connected to the actuator, the program module providing a first driving instruction for controlling the actuator to perform periodic power output; and a position detection module, used to determine the periodic drug infusion amount. When the drug infusion amount reaches a preset threshold, the position detection module and/or the program module provide the actuator with a second driving instruction.

A cradle securely mounts one or more infusion pumps to a pole without obstructing the display, buttons, or connector ports of the infusion pumps. A lower portion of the cradle includes connection pins sized/oriented to fit within respective connection holes of the infusion pump as well as an integrated strain relief mechanism for one or more cables. An upper portion of the cradle includes clamps for engaging a protrusion/ridge on a top surface of the infusion pumps. In a single cradle configuration, a recess within a back surface of the cradle mates with a pole clamp connector or a mounting bar in either a vertical or horizontal orientation. In a multiple cradle configuration, each cradle is secured indirectly to the pole clamp connector via a mounting bar and respective adapters. The mounting bar may be bent to introduce an offset between adjacent infusion pumps.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.

A drug delivery device (1) includes a delivery unit, an electronic control system and a plunger sensing system (70). The delivery unit (3) includes a drug container (6) comprising a barrel portion (6a) and a plunger (12) slidably mounted within the barrel portion and sealing against an inner surface of the barrel portion (6a) for containing a liquid drug (78) within the drug container. The plunger sensing system (70) includes an optical sensor (71) with a transmitter (71a) and a receiver (71b), the transmitter configured for transmitting an optical signal to a back end (73) of the plunger (12) and the receiver configured to receive the optical signal reflected off the plunger back end (73). The plunger sensing system is connected to the electronic control system (47) configured to measure a time of flight of the optical signal from the transmitter to the receiver and to determine therefrom a position of the plunger within the cylinder portion of the drug container.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Systems, storage media and computer-readable media are provided for translating one or more therapy parameters of a first insulin therapy system to one or more translated therapy parameters for use at a second insulin therapy system that is different than the first insulin therapy system. A therapy profile generated at the first insulin therapy system can be send to a translation service. The therapy profile includes one or more therapy parameters. At least one therapy parameter from the therapy profile can be translated into at least one translated therapy parameter that is mapped to and adapted for use by the second insulin therapy system. The at least one translated therapy parameter can then be sent to the second insulin therapy system for use at the second insulin therapy system.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Systems, storage media and computer-readable media are provided for translating one or more therapy parameters of a first insulin therapy system to one or more translated therapy parameters for use at a second insulin therapy system that is different than the first insulin therapy system. A therapy profile generated at the first insulin therapy system can be send to a translation service. The therapy profile includes one or more therapy parameters. At least one therapy parameter from the therapy profile can be translated into at least one translated therapy parameter that is mapped to and adapted for use by the second insulin therapy system. The at least one translated therapy parameter can then be sent to the second insulin therapy system for use at the second insulin therapy system.

The invention relates to a sterile, ready-to-use, stable aqueous solution of ketamine suitable for direct intravenous infusion to a patient in need thereof, wherein the composition is disposed within a sealed infusion container as a premixture. The invention further relates to aqueous solutions of ketamine that are free of antimicrobials such as benzethonium chloride and are shelf-stable. The pharmaceutical compositions can be used, for example, wherein the subject is in need of anesthesia for a diagnostic or a surgical procedure.